Related Experiment Video
Updated: Dec 1, 2025

Studying Wnt Signaling During Patterning of Conducting Airways
Published on: October 16, 2016
mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function decline
Kseniya Obraztsova1,2, Maria C Basil1,2, Ryan Rue1
1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Lymphangioleiomyomatosis (LAM) is a rare fatal cystic lung disease due to bi-allelic inactivating mutations in tuberous sclerosis complex (TSC1/TSC2) genes coding for suppressors of the mechanistic target of rapamycin complex 1 (mTORC1). The origin of LAM cells is still unknown. Here, we profile a LAM lung compared to an age- and sex-matched healthy control lung as a hypothesis-generating approach to identify cell subtypes that are specific to LAM. Our single-cell RNA sequencing (scRNA-seq) analysis reveals novel mesenchymal and transitional alveolar epithelial states unique to LAM lung. This analysis identifies a mesenchymal cell hub coordinating the LAM disease phenotype. Mesenchymal-restricted deletion of Tsc2 in the mouse lung produces a mTORC1-driven pulmonary phenotype, with a progressive disruption of alveolar structure, a decline in pulmonary function, increase of rapamycin-sensitive expression of WNT ligands, and profound female-specific changes in mesenchymal and epithelial lung cell gene expression. Genetic inactivation of WNT signaling reverses age-dependent changes of mTORC1-driven lung phenotype, but WNT activation alone in lung mesenchyme is not sufficient for the development of mouse LAM-like phenotype. The alterations in gene expression are driven by distinctive crosstalk between mesenchymal and epithelial subsets of cells observed in mesenchymal Tsc2-deficient lungs. This study identifies sex- and age-specific gene changes in the mTORC1-activated lung mesenchyme and establishes the importance of the WNT signaling pathway in the mTORC1-driven lung phenotype.
Insights
Lymphangioleiomyomatosis (LAM) is a rare lung disease caused by TSC1/TSC2 gene mutations. This study reveals novel cell states in LAM lungs and identifies a mesenchymal cell hub driving the disease, highlighting WNT signaling
Area of Science:
- Pulmonary Medicine
- Genetics
- Cell Biology
Background:
- Lymphangioleiomyomatosis (LAM) is a rare, fatal cystic lung disease.
- It results from mutations in TSC1/TSC2 genes, affecting mTORC1 signaling.
- The cellular origin of LAM remains unclear.
Purpose of the Study:
- To identify cell subtypes specific to LAM lungs using single-cell RNA sequencing.
- To investigate the role of mesenchymal cells and WNT signaling in LAM pathogenesis.
- To understand the sex- and age-specific gene expression changes in LAM.
Main Methods:
- Single-cell RNA sequencing (scRNA-seq) of LAM and control lungs.
- Mesenchymal-restricted Tsc2 deletion in mouse models.
- Genetic manipulation of WNT signaling pathways.
Main Results:
- Discovery of novel mesenchymal and transitional alveolar epithelial cell states unique to LAM.
- Identification of a mesenchymal cell hub coordinating the LAM phenotype.
- Mice with Tsc2 deficiency showed mTORC1-driven lung disruption, WNT ligand increase, and female-specific gene changes.
- WNT pathway modulation affected mTORC1-driven lung phenotypes, but WNT activation alone did not cause LAM-like disease.
- Distinct crosstalk between mesenchymal and epithelial cells was observed in Tsc2-deficient lungs.
Conclusions:
- The study identifies novel cell states and a mesenchymal hub in LAM lungs.
- It establishes the importance of WNT signaling in the mTORC1-driven lung phenotype.
- Findings highlight sex- and age-specific gene changes in mTORC1-activated lung mesenchyme.
Related Concept Videos
The Effect of Aging on Tissues
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

